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Recombinant porcine growth hormone (rPGH) was solubilised from inclusion bodies (lB's) using either 6 M guanidinium hydroehloride (GnHCI). 
7.5 M urea or by a novel method using a cationic surfactant, cetyltrimeth)'lal~monium chloride (CTAC). Circular dichroism (CD) analysis of the 
secondary (2 °) structure of the urea- and GnHCl-sol ubilised rPG H showed the absence of,r-helical content with the majority of the molecule xisting 
in a "random coil" structure. In contrast, the CTAC-solabilised rPGH displayed significant starting 2 ° structure (10-15% ~ helix; 30-40% fl 
structure). The three rPGH preparations were refolded in vitro against weak urea, GnHCI or aqueous buffers, resulting in an average refolding 
¢ffieiel~cy of 50% native (monomeric) rPGH for CTAC solubilised IB's and only 20% for urea or GnHCI solubilised IB's. We conclude that the 
method of solubilisation of IB's and the resultant difference in the starting 2 ° structure of rPGH, particularly ,r.helical content, is a major in vitro 
factor that apparently predetermines the aggregation/refolding behaviour rPGH irrespective of refolding environment. 
In vitro refolding" Secondary structure; Cationic surfactant', Growth hormone; Inclusion body 
1. INTRODUCTION 
In common with the high-level expression of many 
eukaryotic proteins in bacteria, expression of animal 
growth hormones in E. coli results in their deposition 
within large proteinaceous aggregates or inclusion bod- 
ies [1-5]. The formation of these IB's is often considered 
undesirable since the deposited protein can only be sol- 
ubilised using strong denaturants such as 6 M GnHCI, 
or 7.5 M urea or under other harsh conditions [6-9]. 
The use of high concentrations of urea and/or GnHCI 
results in the loss of secondary structure of solubilised 
proteins with the protein molecule xisting mostly in the 
so called 'random coil' formation [10]. 
The denaturation f recombinant proteins during sol- 
ubilisation from IB's necessitates that they be 'refolded', 
that is, renatured in vitro to regain native confirmation. 
For intramolecular disulphide linked proteins uch as 
rPGH, the in vitro formation of undesirable high molec- 
ular-weight aggregates due to aberrant intermolecular 
disulphide bonding is a major problem limiting recov- 
ery of native (i.e. monomeric 22K) protein. We have 
recently reported a novel method for solubilising recom- 
binant proteins from IB's [11] using a cationic surfac- 
taut, cetyltrimethylammonium chloride (CTAC). We 
show here that rPGH solubilised using CTAC displays 
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considerable differences in secondary structure, particu- 
larly ~-helical content, in comparison with urea/GnHCl 
solubilised rPGH. The relationship between different 
starting secondary structure and subsequent in vitro 
refolding yield and efficiency of formation of native 
(monomeric) over aggregated (denatured) rPGH was 
examined for three different refolding environments 
and the results related to the "framework' model of 
protein folding [12]. 
2. MATERIALS AND METHODS 
2,1. Sohtbilisation attd refolding of rPGH 
Methionyl rPGH was expressed in E. coli and IB's purified as 
described previously [11,13]. The IB's from fermentation batch FI35 
(dry weight 90 mg/ml) were solubilised in 25 mM ethanolamine-HCI 
pH 10.0 containing 1% (v/v) 2.mereaptoethanol and either 7.5 M urea. 
6.0 M GnHCI or 5% (w/v) CTAC for i--2 h at ambient emperature 
or 55°C as described previously [11.13]. Approximately 50 mg dry 
weight of IB's was solubilized in 3 ml of each buffer and I ml allq uots 
of each of the solubilised rPGH preparations were subsequently re- 
folded by dialysis, ":-t a concentration of 2-3 m~/ml against 25 mM 
ethanolamine-HCl pH 10.0 with or without 3 M urea or I M GnHCI. 
gefolding was for 48-72 h at 4°C with shaking and aeration and a 
total of 9 different solubilisation/rcfolding combinations resulted. 
2.2. HPLC analysis 
Reversed-phase HPLC (RP-HPLC) analyses to quantitale the 
amount of oxidised and monomeric rPGH as a % of the total rcfolded 
protein (monomeric and aggregated fractions) were performed and 
validated with purified oxidised monomgric, reduced, and "aggre- 
gated' rPGH standards as described previously [i1,13]. 
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2.1. Prfyrr:dritvl (Ij’ IiS ~vnlcridji~r CD flrld~y 
For CD analysts. IB’s were further purllled by sucrose-gritdicnt 
centrifugation. Briefly. lhc IBs were resuspended in IO mM Tris-HCI, 
0.X M sucrose, I mM EDTA pH 8,O and layered on10 a slepwisc 
gradicnl consisting of equal volumes of 678, 53% and 40% (W/V) 
sucrose in I mM Tris-HCI, I mM EDTA, pH 8.0. The final gradient 
was established by cenirilkgation at 108.000~~ for ? h. The Is’s ap- 
pcnred as a white band at the 53-676 sucrose imerlice and were 
collecled with a Pasteur pipette. and washed thrice with MilliQ water, 
The linal protein pellet. cquivalcnt to approximately 45 mg dry weight 
was resuspended in 4.5 ml or solubilisation bulTer containing 6.4 M 
GnHCI. 8.0 M urea or 5% (w/v) CTAC in 50 mM glycine. 0.25 M 
2.mcrcup~oothanol pt-i 10. Solubilisation was conducted Tar I h at 
55°C. Al’tcr solubilisation. the fret thiols on the prokin were blocked 
by the addition of 0.5 ml of a 2 M solution orcystcinc in 0.6 M HCI 
and the mixture rurther incubated for 30 min u 5S°C. The solubiliscd 
samples were [hen exchanged twice with bulTers containing 6.3 M 
GnHCI, 8.0 M urea or 5% (w/v) CTAC in 50 mM glycinr: pH 9. I using 
Cenlricon-IO concentrators (Amicon), The solubiliscd samples were 
fihered through a 0.23 pm lilter and then centrirugcd at 13.000~~ for 
5 min prior to use. 
2.4. Prordn e.rrintari0n.s 
Samples were preciphatcd with etl,anol (90% (v/v) Anal concentra- 
tion), vortexed. incubated at -X’C l-or 30 min, centrifuged at 
13,000~~ for I5 min. resuspended in 0.225 M FiaOH ;md protein 
content cstimatcd by the Lcwry method [ 141. 
2.5. Circular dichroistn (CD) measurcmenls 
CD analyses were conducted us described previously [I I]. CD mcas- 
urcmenls were cdnduc~cd in the presence ol’the solubilisarion rcagcnt 
used, that is, 6.4 M Gn.HCI. 8.0 M urea or 5% (w/v) CTAC in 50 mM 
glycinc buffer pH 9.1. 
3. RESULTS AND DISCUSSION 
tiorts 
The peptide absorption spectra (;2. c 240 nm) of re- 
duced rPGH preparations olubilised from IB’s were 
examined between 200-250 nm in order to estimate the 
secondary structure of urea-, GnHCI- and CTAC-solu- 
bilised proteins. Typical CD spectra are shown in Fig. 
1. Notable differences were apparent between the CD 
spectrum of CTAC-solubilised rPGH and the spectral 
curves for urea/GnHCl-solubilised protein. The CTAC- 
solubilised proteins were calculated to comprise ap 
proximately 10-l 5% a helix; IO-15% ,6 sheet; 20-250/o 
/? turn and 40-50% ‘random-coil’ structure. In contrast, 
the urea/GnHCl-derived rPGH displayed no a-helical 
structure, apparently comprising 40-50% /3 turns and 
40-508 random coil structure. While the large compo- 
nents of apparently unordered ‘random coil’ structures 
in these proteins mean that the values for ordered struc- 
tural components (a-helical and 1 structures) should be 
regarded as approximate, the differences in values (par- 
ticularly a helix) clearly reflect he observed ifferences 
in the respective shapes of the CD spectral curves: nota- 
bly at the negative n-n * band near 220 nm which is 
characteristic of a-helical content (cf. Fig. I, curve c). 
The values for/3 turns/sheet and ‘random coil’ structure 
assignments are generally regarded as less reliable than 
178 
-15-1 
200 210 220 230 240 250 
WAVELENGTH (nm) 
Fig. I. CD spectra ol’rPGH solubiliscd liom ID’s using in part (a) 8.0 
M urea/O.25 M kncrcaptoelhanol; (b) G M GnHCV0.25 M 2.mcrcup- 
toethanol and (c) 5% (w/v) CTAC and 0.25 M 2mercaptoetbanoI. The 
8 values are the calculated measures of the mean residue cllipticities. 
CD spectral nzalyris was performed US described previously [I I]. 
for ct helix, within the accepted limits of CD analysis of 
denatured proteins (17-19). 
3.2. Refdding oJ ww, Gn HCI- cd CTA C-soltrbilised 
Recombinant proteins solubilised from IS’s using 
chaotrophic agents in a ‘strongly’ denaturing environ- 
ment (7.5 M urea or G M GnHCI) are commonly re- 
natured in vitro in ‘weakly’ denaturing environments 
using 0.5-2 M GnHCl or l-4 M urea [7-9,153. To exam- 
ine the relative contribution of different methods of 
solubilisation and therefore the starting 2” structure, 
and the in vitro refolding environment i self on yield of 
native (i.e. monomeric 21.X) rPGH, we used three 
simple refolding environments; 3 M urea, 1 M GnHCl 
or a weak aqueous buffer for each of the three solubil- 
ised rPGH preparations. A total of 9 different solubili- 
sation-refolding combinations were therefore exam- 
ined. The proportion of native (monomeric) rPGH after 
refolding was estimated by RP-HPLC using a method 
we have previously validated and used to separate mon- 
omeric 21.5K rPGH from polydisperse high mol. wt. 
rPGH or other contaminants [11,13]. A typical RP- 
HPLC profile of refolded rPGI-I is shown in Fig. 2, with 
differences in retention time of between l-l.5 min for 
monomeric (native) and ‘aggregated’ rPGH or other E. 
cofi contaminants. 
The results of the nine solubilisation-refolding com- 
binations examined are shown in Table I as the % yield 
of monomeric rPGH in each case, as well as an average 
% refolding efliciency for either CTAC, urea or GnHCl 
solubilised IB’s. For a given solubilisation-refolding 
combination, the % yield of monomeric rPGH using 
CTAC-solubilised 113’s was clearly between 2- to 4-fold 
greater than that with urea- or GnHCl-solubiliaed IB’s, 
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irrespective of the in vitro refolding environment used 
(Table I; column 3). Moreover, the average fficiency of 
formation of native rPGH was respectively 50% for 
CTAC-solubiliscd against 20% for urea- or GnHCl- 
solubilised Et’s, suggesting that selection of the method 
of solubilisation and the resulting differences in sccond- 
ary structure were more important for influencing the 
yield of native protein than the in vitro refolding envi- 
ronment . 
4. CONCLUSIONS 
We have used in this study a novel method of solubil- 
ising rPGH from IB’s with significant retention of 2” 
structure, notably a-helical content. This has allowed 
for the first time an experimental determination of 
whether the starting 2O structure of a protein (rPGH) 
solubilised using surfactant, urea or GnHCl in any way 
predisposes the protein to a particular in vitro refolding 
pathway, or whether the in vitro refolding environment 
used is the major influence on the proportion of native 
rPGH recovered. Our results clearly show that rPGH 
from IB’s solubilised using the cationic surfactant 
CTAC was substantially less prone to in vitro aggrega- 
tion, resulting in higher average recovery of native 
structure irrespective of the three refolding environ- 
ments used. This effect is unlikely to be due to CTAC 
offering any ‘nonspecific’ protection against aggrega- 
tion as any residual surfactant bound to protein is re- 
Table I 
The cffcct of various solubilisation und in-vitro refolding environ- 
mcnts on the yield of monomeric (native) rPGH 
Method of 
solubilisation 
Method of 
refolding’ 
8 monomeric Average % 
rPGH? refolding 
efficiency’ 
I. 5% (w/v) CTAC aqueous buffer 10 
3 M urea 33 50 
1 M GnHCl 20 
2. 7.5 M Urea aqueous buffer IO 
3 M urea 15 22 
1 M GnHCl IO 
3.6 M GnHCl aqueous bufYer B 
3 M urea I5 20 
1 M GnHCl 8 
’ Refolding was performed in 25 mM ethanolaminc-HCI buffer pi-i 
10.0 with and witbout 3 M urea or I M GnHCl at a rPGH concentra- 
tion of approximately 2 mdml for 48-71 h at WZ with aeration. 
’ % monomeric rPGl-l was estimated by RP-HPLC a5 validated and 
described previously [I 1.131. 
‘Calculated as the average of the % monomeric rPGH yields shown 
in column 3, that is, 25%. I I % and IO% for respcctivcly the CTAC-, 
urea- and GnHCl-solubiliscd rPGH divided by the percentage of 
reduced rPGH at the start of in vitro refolding as previously daer- 
mined for the ID’s used [I I]. 
A280 
0.500 
RT-(min) 
Fig. 2. Example of RP-HPLC analysis of in vitro rcroldcd rPGH 
solubilised from II3’s using CTAC. The monomeric (M) rPGH peak 
is clearly rcsolvablc from polydispenc ‘aggregated’ rPGH and E. co/i 
contaminants, as validated and described previously [I 1,131 using 
SDS-PAGE and standard preparations of monomeric rPGl-I. 
moved by a cation exchange step prior to commencing 
in vitro refolding. 
We have previously established using CD analysis 
that correctly refolded .rPGH comprises approximately 
3540% a helix [1 I]. In the present study, reduced, 
CTAC-solubilised, that is, ‘unfolded’ #GM still com- 
prised approximately lo-158 a helix. It would aTpear 
that the notable differences in starting secondary struc- 
ture between CTAC-urea- and GnHCl-solubiliscd 
rPGH do predispose the in vitro refolding behaviour of 
rPGH although a direct casual relationship with yield 
of native, monomeric protein remains to be established. 
However, these results are consistent with the ‘frame- 
work’ mode1 of protein folding [12] which postulates 
that the presence of localised secondary structures plays 
a central role in determining the folding pathway, as 
well as a recent report [16] demonstrating the native-like 
structure of refolding intermediates. This suggests that 
the structures of refolding intermediates and the protein 
folding pathway reflect he stability of secondary struc- 
tural units and assemblies that would normally be found 
in the native protein. In the case of surfactant-solubil- 
ised rPGH, starting in vitro refolding with an apparent 
‘intermediate’ displaying definite 2” structural compo- 
nents of the native state, is clearly beneficial. On a more 
practical evel, the use of CTAC to solubilise other re- 
combinant proteins from IB’s may represent an ap- 
proach offering similar advantageous in vitro refolding 
behaviour to that reported here for rPGH. Alterna- 
tively, the conditions for solubilisation of insoluble re- 
combinant proteins, particularly the GnHCl or urea 
concentration used, could be carefully selected to give 
an acceptable level of solubilisation together with, if 
possible. retention of some protein 2” structure prior to 
commencing in vitro refolding. 
179 
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